Payment overview · 2025
General Payments
$570.47
25 reported records · 19 companies
Healthcare provider profile · identity verified
Mohammed Syed, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLINT, MI · NPI 1639210669
Verified facts
What the public records show
CMS Open Payments records show Mohammed Syed, MD received $570.47 in general payments during 2025 across 25 reported records.
Merck Sharp & Dohme LLC accounted for 11.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $67.74 | 11.9% | 4 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $53.62 | 9.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.56 | 8.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.36 | 7.4% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $34.81 | 6.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.84 | 5.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.99 | 5.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.41 | 5.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.71 | 5.2% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $26.96 | 4.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.70 | 4.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.37 | 3.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.29 | 3.7% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $19.05 | 3.3% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.11 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.64 | 2.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.02 | 2.8% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.66 | 2.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.63 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $570.47 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $67.74 | 4 | 2025 |
Source payment records
|
|||||
| BARRIGEL Normalized: barrigel |
Device | Teleflex LLC | $53.62 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $49.56 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.36 | 2 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $34.81 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $33.84 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $32.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.41 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.71 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| VPRIV Normalized: vpriv |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
83 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 607 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 523 | 148 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 333 | 97 |
| Omeprazole | Omeprazole | 304 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 301 | 78 |
| Metformin Hcl | Metformin Hcl | 267 | 70 |
| Losartan Potassium | Losartan Potassium | 250 | 68 |
| Lisinopril | Lisinopril | 158 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 130 | 28 |
| Meloxicam | Meloxicam | 119 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 34 |
| Carvedilol | Carvedilol | 99 | 26 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 93 | 39 |
| Furosemide | Furosemide | 93 | 20 |
| Allopurinol | Allopurinol | 92 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 32 |
| Gabapentin | Gabapentin | 84 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 83 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 29 |
| Simvastatin | Simvastatin | 78 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 19 |
| Eliquis | Apixaban | 68 | 15 |
| Atenolol | Atenolol | 67 | 15 |
| Jardiance | Empagliflozin | 61 | 22 |
| Ozempic | Semaglutide | 59 | 15 |
| Trulicity | Dulaglutide | 58 | 16 |
| Potassium Chloride | Potassium Chloride | 55 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 19 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 51 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 19 |
| Sertraline Hcl | Sertraline Hcl | 47 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 22 |
| Clonidine Hcl | Clonidine Hcl | 44 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 14 |
| Lovastatin | Lovastatin | 41 | suppressed |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Baclofen | Baclofen | 39 | 17 |
| Bumetanide | Bumetanide | 36 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 12 |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 33 | 11 |
| Ibuprofen | Ibuprofen | 33 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 23 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 15 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | 12 |
| Fluconazole | Fluconazole | 25 | 16 |
| Tradjenta | Linagliptin | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 20 |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Klor-Con M15 | Potassium Chloride | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Se-Natal 19 | Pnv No.118/Iron Fumarate/Fa | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $570.47 · 25 records | Merck Sharp & Dohme LLC | APTIMA, BARRIGEL, BREZTRI, CAPLYTA, EDARBI, FANAPT, OTEZLA, Ohtuvayre, REPATHA, REXULTI, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VERQUVO, VIVITROL, VPRIV, VRAYLAR, VYNDAQEL, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error